ClinicalTrials.gg
RecruitingNCT07124130Updated Aug 22, 2025

Lactated Ringer's and Dextrose 5% vs Only Lactated Ringer's in Labor

A Phase 4 interventional study of 5% Dextrose (D5) in Normal Saline (NS) and Lactate Ringer in Induced Labor, sponsored by Eastern Virginia Medical School. Recruiting at 2 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Eastern Virginia Medical School · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
Phase
Phase 4
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this clinical trial is to determine which of two types of standard intravenous (IV) fluids (a combination of 5% dextrose and Lactated Ringers solution and Lactated Ringers solution alone) has a better influence on labor when inducing labor in pregnant women. The main questions it aims to answer are:

  1. Does the use of 5% dextrose and Lactated Ringers lead to a shorter labor than the use of just Lactated Ringers?
  2. Does the use of 5% dextrose and Lactated Ringers increase the risk of neonatal hypoglycemia when compared to Lactated Ringers? Participants in this trial will be randomly assigned to one of two groups: a group that receives a solution of 5% dextrose and Lactated Ringers, and a group that receives Lactated Ringers alone. Researchers will compare the outcomes of the two groups to see which IV fluid is more effective.
02

Conditions studied

  • Induced Labor

Keywords

  • Induced labor
  • 5% dextrose
  • Lactated Ringers
  • duration of labor
03

In context

Lead sponsor

Eastern Virginia Medical School is the lead sponsor of 56 studies on the registry; 8 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Nulliparous women
  • Age 18 years or older and able to provide
  • Singleton pregnancy at term
  • Induction of labor
  • Cephalic presentation
  • Unfavorable cervix (Bishop score ≤ 6)

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years
  • Involuntarily confined or detained
  • Considered as having diminished decision-making capacity
  • Spontaneous labor (cervical exam between 5-6 cm) with or without ruptured membraned
  • Favorable cervix (Bishop score >6)
  • Diabetes mellitus (both gestational and pre-gestational)
  • Structural renal disease
  • Acute or chronic kidney disease resulting in abnormal creatinine or proteinuria
  • Evidence of chorioamnionitis or non-reassuring fetal testing at the time of enrollment
  • Pyrexia (>38.0 degrees Celsius)
  • Stillbirth
  • Planned cesarean delivery
  • Women presenting with emergent circumstances for labor induction
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
158 participants (estimated)

Study arms

  • Active comparator
    5% dextrose and Lactate Ringer

    Participants randomized to this arm will receive an intravenous solution of 5% dextrose and Lactate Ringer during labor.

    Drug: 5% Dextrose (D5) in Normal Saline (NS) · Drug: Lactate Ringer

  • Active comparator
    Lactate Ringer only

    Participants randomized to this arm will receive an intravenous Lactate Ringer solution only.

    Drug: Lactate Ringer

Interventions

  • Drug5% Dextrose (D5) in Normal Saline (NS)

    A solution of 5% dextrose and lactate ringer will be given to one group of participants.

  • DrugLactate Ringer

    A Lactate Ringer solution will be given to one group of participants.

06

What researchers measure

Primary outcomes

  1. Time from Induction Start To Delivery

    Time frame: From enrollment to the end of labor

Secondary outcomes

  1. Type of amniotomy

    Spontaneous vs artificial

    Time frame: From enrollment until delivery

  2. Mode of Delivery

    The incidence of spontaneous vaginal delivery, operative vaginal delivery and cesarean delivery.

    Time frame: From enrollment until delivery.

  3. Indication for cesarean delivery

    Rate of failed induction of labor, arrest of active phase, arrest of descent, non-reassuring fetal condition, maternal request, other.

    Time frame: From enrollment until delivery.

  4. Delivery within 12 hours of induction.

    Incidence of delivery within 12 hours of induction.

    Time frame: Time from induction until delivery.

  5. Delivery within 24 hours of Induction

    Incidence of delivery within 24 hours of induction.

    Time frame: Time of induction to time of delivery.

  6. Delivery within 36 hours of Induction

    Incidence of delivery within 36 hours of induction.

    Time frame: From time of induction to time of delivery.

  7. Delivery within 48 hours of Induction

    Incidence of delivery within 48 hours of induction.

    Time frame: From time of induction to time of delivery.

  8. Perineal Lacerations (Degree I-IV)

    Degree of perineal lacerations occurring during delivery (first to fourth degree).

    Time frame: From time of enrollment to time of delivery.

  9. Postpartum hemorrhage

    Blood loss \>1000 mL

    Time frame: Time of enrollment to time of delivery.

  10. Blood Transfusion

    Incidence of blood transfusions required during or after delivery.

    Time frame: From time of enrollment to hospital discharge (up to 42 days post-delivery).

  11. Isolated maternal fever

    Incidence of maternal fever (T\>38°C)

    Time frame: From time of enrollment to hospital discharge (up to 42 days post-delivery).

  12. Diagnosed Endometritis

    The number of endometritis based on clinical signs and diagnostic tests.

    Time frame: From time of enrollment to hospital discharge (up to 42 days post-delivery).

  13. Wound Separation/Infection

    Incidence of wound separation or infection requiring additional closure or antibiotics.

    Time frame: From time of enrollment to hospital discharge (up to 42 days post-delivery).

  14. Intraamniotic Infection

    Presence of maternal fever, tachycardia, and/or fundal tenderness suggesting intraamniotic infection.

    Time frame: From time of enrollment to hospital discharge (up to 42 days post-delivery).

  15. Venous Thromboembolism (VTE)

    Occurrence of venous thromboembolism.

    Time frame: From time of enrollment to hospital discharge (up to 42 days post-delivery).

  16. Hysterectomy

    Occurrence of hysterectomy related to delivery complications.

    Time frame: From time of enrollment to hospital discharge (up to 42 days post-delivery).

  17. Intensive Care Unit (ICU) Admission

    Admission to ICU for maternal complications.

    Time frame: From time of enrollment to ICU admission (up to 42 days post-delivery).

  18. Maternal Death

    Occurrence of maternal death during or after delivery.

    Time frame: From time of enrollment until maternal death (up to 42 days post-delivery).

  19. Length of hospital stay

    Days between admission and discharge

    Time frame: From time of hospital admission to time of hospital discharge (up to 50 days post-delivery).

  20. Cord Prolapse

    Occurrence of cord prolapse during labor.

    Time frame: From time of enrollment to delivery.

  21. Use of Terbutaline

    The number of terbutaline use for uterine contractions.

    Time frame: From time of enrollment to delivery.

  22. Placement of Intrauterine Pressure Catheter

    The number of placement of intrauterine pressure catheter during labor.

    Time frame: From time of enrollment to delivery.

  23. Epidural Use

    Use of epidural anesthesia during labor for pain relief.

    Time frame: From time of enrollment to delivery.

  24. Neonatal Severe Respiratory Distress Syndrome (RDS)

    Need for intubation and mechanical ventilation for ≥12 hours.

    Time frame: From time of delivery to hospital discharge. Includes the entire length of neonate's hospital stay, up to 1 year following delivery.

  25. Neonatal 5- minute Apgar score <7

    Incidence of 5-minute Apgar score\<7

    Time frame: From time of delivery up to 1 day following delivery.

  26. Arterial umbilical cord pH <7

    Incidence of arterial umbilical cord pH \<7

    Time frame: From time of enrollment up to 1 day following delivery.

  27. Neonatal outcome composite

    Incidence of neonatal outcome composite

    Time frame: From time of delivery to hospital discharge. Includes the entire length of neonate's hospital stay, up to 1 year following delivery.

  28. Neonatal Sepsis (Culture-proven or Presumed)

    Incidence of neonatal sepsis, culture-proven or presumed.

    Time frame: From time of delivery to hospital discharge. Includes the entire length of neonate's hospital stay, up to 1 year following delivery.

  29. Neonatal Intensive Care Unit (NICU) Admission

    Admission of neonate to NICU.

    Time frame: From time of delivery to NICU admission. Includes the entire length of neonate's hospital stay, up to 1 year following delivery.

  30. Hypoxic-Ischemic Encephalopathy

    Diagnosis of hypoxic-ischemic encephalopathy in neonates.

    Time frame: From time of delivery to hospital discharge. Includes the entire length of neonate's hospital stay, up to 1 year following delivery.

  31. Neonatal Intraventricular Hemorrhage (Grade 3 or 4)

    Occurrence of grade 3 or 4 intraventricular hemorrhage in neonates.

    Time frame: From time of enrollment to hospital discharge. Includes the entire length of neonate's hospital stay, up to 1 year following delivery.

  32. Diagnosed Neonatal Necrotizing Enterocolitis

    The number of diagnosis of necrotizing enterocolitis in the neonate.

    Time frame: From time of delivery to time of hospital discharge. Includes the entire length of neonate's hospital stay, up to 1 year following delivery.

  33. Neonatal Head Cooling Therapy

    Use of head cooling therapy for neonates to prevent brain injury.

    Time frame: From time of delivery to time of hospital discharge. Includes the entire length of neonate's hospital stay, up to 1 year following delivery.

  34. Neonatal Blood Transfusion

    Need for blood transfusion in the neonate.

    Time frame: From time of delivery to time of hospital discharge. Includes the entire length of neonate's hospital stay, up to 1 year following delivery.

  35. NICU Stay >48 hours

    Incidence of NICU stay lasting longer than 48 hours.

    Time frame: From NICU admission to NICU discharge. Includes the entire length of neonate's hospital stay, up to 1 year following delivery.

  36. Neonatal Length of Stay (days)

    Total length of neonatal stay in the hospital.

    Time frame: From time of delivery to time of hospital discharge. Includes the entire length of neonate's hospital stay, up to 1 year following delivery.

  37. Bishop Score: Cervical Dilation, Effacement, Station, Position, Consistency

    Baseline Bishop score (0-13, with 13 being more favorable to labor) and its changes during labor to assess cervical readiness for induction.

    Time frame: From time of enrollment to time of induction up to 1 week.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Greenland S. Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. Epidemiology. 1995 Jul;6(4):450-4. doi: 10.1097/00001648-199507000-00025. No abstract available. PubMed 7548361 ↗
  • Carbone JF, Tuuli MG, Fogertey PJ, Roehl KA, Macones GA. Combination of Foley bulb and vaginal misoprostol compared with vaginal misoprostol alone for cervical ripening and labor induction: a randomized controlled trial. Obstet Gynecol. 2013 Feb;121(2 Pt 1):247-252. doi: 10.1097/AOG.0b013e31827e5dca. PubMed 23303106 ↗
  • Moraes Filho OB, Albuquerque RM, Cecatti JG. A randomized controlled trial comparing vaginal misoprostol versus Foley catheter plus oxytocin for labor induction. Acta Obstet Gynecol Scand. 2010 Aug;89(8):1045-52. doi: 10.3109/00016349.2010.499447. PubMed 20636243 ↗
  • Gomez Slagle HB, Fonge YN, Caplan R, Pfeuti CK, Sciscione AC, Hoffman MK. Early vs expectant artificial rupture of membranes following Foley catheter ripening: a randomized controlled trial. Am J Obstet Gynecol. 2022 May;226(5):724.e1-724.e9. doi: 10.1016/j.ajog.2021.11.1368. Epub 2022 Feb 6. PubMed 35135684 ↗
  • Berry M, Lamiman K, Slan MN, Zhang X, Arena Goncharov DD, Hwang YP, Rogers JA, Pacheco LD, Saade GR, Saad AF. Early vs delayed amniotomy following transcervical Foley balloon in the induction of labor: a randomized clinical trial. Am J Obstet Gynecol. 2024 May;230(5):567.e1-567.e11. doi: 10.1016/j.ajog.2024.01.028. Epub 2024 Feb 15. PubMed 38367749 ↗
  • Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340:c332. doi: 10.1136/bmj.c332. PubMed 20332509 ↗
  • WHO recommendations: Intrapartum care for a positive childbirth experience. Geneva: World Health Organization; 2018. Available from http://www.ncbi.nlm.nih.gov/books/NBK513809/ PubMed 30070803 ↗
  • Shafaie FS, Mohaddesi H, Mirghafourvand M, Yulghunlu FA. A randomized, double-blinded, controlled trial comparing parenteral dextrose 5%, Ringer's solution and oral intake on the delivery outcomes in nulliparas. Int J Womens Health 2017;283-9.
  • Cowett RM, Susa JB, Giletti B, Oh W, Schwartz R. Glucose kinetics in infants of diabetic mothers. Am J Obstet Gynecol. 1983 Aug 1;146(7):781-6. doi: 10.1016/0002-9378(83)91077-3. PubMed 6346883 ↗
  • Dapuzzo-Argiriou LM, Smulian JC, Rochon ML, Galdi L, Kissling JM, Schnatz PF, Gonzalez Rios A, Airoldi J, Carrillo MA, Maines J, Kunselman AR, Repke J, Legro RS. A multi-center randomized trial of two different intravenous fluids during labor. J Matern Fetal Neonatal Med. 2016;29(2):191-6. doi: 10.3109/14767058.2014.998190. Epub 2015 Sep 4. PubMed 25758624 ↗
  • Cerri V, Tarantini M, Zuliani G, Schena V, Redaelli C, Nicolini U. Intravenous glucose infusion in labor does not affect maternal and fetal acid-base balance. J Matern Fetal Med. 2000 Jul-Aug;9(4):204-8. doi: 10.1002/1520-6661(200007/08)9:43.0.CO;2-9. PubMed 11048829 ↗
  • Fisher AJ, Huddleston JF. Intrapartum maternal glucose infusion reduces umbilical cord acidemia. Am J Obstet Gynecol. 1997 Oct;177(4):765-9. doi: 10.1016/s0002-9378(97)70265-5. PubMed 9369816 ↗
  • Pare J, Pasquier JC, Lewin A, Fraser W, Bureau YA. Reduction of total labor length through the addition of parenteral dextrose solution in induction of labor in nulliparous: results of DEXTRONS prospective randomized controlled trial. Am J Obstet Gynecol. 2017 May;216(5):508.e1-508.e7. doi: 10.1016/j.ajog.2017.01.010. Epub 2017 Jan 30. PubMed 28153654 ↗
  • Philipson EH, Kalhan SC, Riha MM, Pimentel R. Effects of maternal glucose infusion on fetal acid-base status in human pregnancy. Am J Obstet Gynecol. 1987 Oct;157(4 Pt 1):866-73. doi: 10.1016/s0002-9378(87)80075-3. PubMed 3314516 ↗
  • Collinot H, Merrer J, Girault A, Goffinet F, Le Ray C. Implementation of glucose 5% supplementation protocol to reduce the duration of labor among women with cervical ripening by prostaglandins: The GLUCOSHORT before-and-after study. J Gynecol Obstet Hum Reprod. 2023 May;52(5):102558. doi: 10.1016/j.jogoh.2023.102558. Epub 2023 Feb 19. PubMed 36806716 ↗
  • Sharma C, Kalra J, Bagga R, Kumar P. A randomized controlled trial comparing parenteral normal saline with and without 5% dextrose on the course of labor in nulliparous women. Arch Gynecol Obstet. 2012 Dec;286(6):1425-30. doi: 10.1007/s00404-012-2485-1. Epub 2012 Aug 4. PubMed 22865033 ↗
  • Shrivastava VK, Garite TJ, Jenkins SM, Saul L, Rumney P, Preslicka C, Chan K. A randomized, double-blinded, controlled trial comparing parenteral normal saline with and without dextrose on the course of labor in nulliparas. Am J Obstet Gynecol. 2009 Apr;200(4):379.e1-6. doi: 10.1016/j.ajog.2008.11.030. Epub 2009 Feb 14. PubMed 19217592 ↗
  • Hernandez Lopez AB, Muriel Miguel C, Fernandez-Canadas Morillo A, Lopez Lapeyrere C, Perez Medina T, Salcedo Marina A, Fornet Ruiz I, Rubio Gonzalez E, Solis Munoz M. Efficacy of "optimal hydration" during labor: HYDRATA study protocol for a randomized clinical trial. Res Nurs Health. 2020 Jan;43(1):8-16. doi: 10.1002/nur.21998. Epub 2019 Dec 2. PubMed 31793019 ↗
  • Nordstrom L, Arulkumaran S, Chua S, Ratnam S, Ingemarsson I, Kublickas M, Persson B, Shimojo N, Westgren M. Continuous maternal glucose infusion during labor: effects on maternal and fetal glucose and lactate levels. Am J Perinatol. 1995 Sep;12(5):357-62. doi: 10.1055/s-2007-994496. PubMed 8540943 ↗
  • Riegel M, Quist-Nelson J, Saccone G, Locci M, Shrivastava VK, Salim R, Fisher A, Nordstrom L, Kunselman AR, Repke J, Fong A, Smulian J, Xodo S, Mokhtari N, Zullo F, Berghella V. Dextrose intravenous fluid therapy in labor reduces the length of the first stage of labor. Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:284-294. doi: 10.1016/j.ejogrb.2018.07.019. Epub 2018 Jul 17. PubMed 30055509 ↗
  • Stratton JF, Stronge J, Boylan PC. Hyponatraemia and non-electrolyte solutions in labouring primigravida. Eur J Obstet Gynecol Reprod Biol. 1995 Apr;59(2):149-51. doi: 10.1016/0028-2243(95)02042-q. PubMed 7657008 ↗
  • Oral E, Gezer A, Cagdas A, Pakkal N. Oxytocin infusion in labor: the effect different indications and the use of different diluents on neonatal bilirubin levels. Arch Gynecol Obstet. 2003 Jan;267(3):117-20. doi: 10.1007/s00404-002-0298-3. PubMed 12552319 ↗
  • Omigbodun AO, Akindele JA, Osotimehin BO, Fatinikun T, Fajimi JL, Adeleye JA. Effect of saline and glucose infusions of oxytocin on neonatal bilirubin levels. Int J Gynaecol Obstet. 1993 Mar;40(3):235-9. doi: 10.1016/0020-7292(93)90836-l. PubMed 8096475 ↗
  • Garmi G, Zuarez-Easton S, Zafran N, Ohel I, Berkovich I, Salim R. The effect of type and volume of fluid hydration on labor duration of nulliparous women: a randomized controlled trial. Arch Gynecol Obstet. 2017 Jun;295(6):1407-1412. doi: 10.1007/s00404-017-4381-1. Epub 2017 May 3. PubMed 28470550 ↗
  • Loong EP, Lao TT, Chin RK. Effects of intrapartum intravenous infusion of 5% dextrose or Hartmann's solution on maternal and cord blood glucose. Acta Obstet Gynecol Scand. 1987;66(3):241-3. doi: 10.3109/00016348709020755. PubMed 3310504 ↗
  • Fong A, Serra AE, Caballero D, Garite TJ, Shrivastava VK. A randomized, double-blinded, controlled trial of the effects of fluid rate and/or presence of dextrose in intravenous fluids on the labor course of nulliparas. Am J Obstet Gynecol. 2017 Aug;217(2):208.e1-208.e7. doi: 10.1016/j.ajog.2017.03.010. Epub 2017 Mar 18. PubMed 28322776 ↗
  • Ahadi Yulghunlu F, Sehhatie Shafaie F, Mirghafourvand M, Mohaddesi H. The effects of intravenous dextrose 5%, Ringer's solution, and oral intake on the duration of labor stages in nulliparous women: a double-blind, randomized, controlled trial. J Matern Fetal Neonatal Med. 2020 Jan;33(2):289-296. doi: 10.1080/14767058.2018.1489792. Epub 2018 Sep 9. PubMed 29909704 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Mar 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Aug 15, 2025
StartEst.
Sep 2025
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07124130
Lead sponsor
Eastern Virginia Medical School
Collaborators
University of Modena and Reggio Emilia
Responsible party
Tetsuya Kawakita, MD (Associate Professor, Eastern Virginia Medical School) — Principal investigator
First posted
Aug 15, 2025
Start date
Sep 2025 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Aug 22, 2025

Study contacts

Tetsuya Kawakita, MD
Contact
kawakit@odu.edu
757-446-7900

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion